Alcohol

Alcohol

SCHEMBL1996535

CCO.CCOC(=O)C(=O)CC(C)=O

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
LMNA P02545 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MAPT P10636 2/20 0.44
GLO1 Q04760 1/20 0.43
GAA P10253 3/20 0.42
MGAM O43451 2/20 0.42
SI P14410 2/20 0.42
MGAM2 Q2M2H8 2/20 0.42
EGLN1 Q9GZT9 1/20 0.41
NPSR1 Q6W5P4 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 2/20 0.38
PKM P14618 1/20 0.38
CYP2D6 P10635 1/20 0.38
FAAH O00519 2/20 0.38
TSHR P16473 1/20 0.38
POLB P06746 1/20 0.37
ALOX15 P16050 1/20 0.37
SOAT1 P35610 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL183336 0.95 ALDH1A1 (0.48) ALDH1A1LMNAHSD17B10MAPTGLO1
SCHEMBL8804853 0.83 GAA (0.52) ALDH1A1LMNAHSD17B10MAPTGLO1
SCHEMBL1983275 0.80 MGAM (0.43) ALDH1A1LMNAHSD17B10MAPTGLO1
SCHEMBL11253654 0.78 ALDH1A1 (0.44) ALDH1A1LMNAHSD17B10MAPTGLO1
SCHEMBL17817681 0.78 GAA (0.48) ALDH1A1LMNAHSD17B10MAPTGLO1
SCHEMBL7633120 0.77 ALDH1A1 (0.47) ALDH1A1LMNAHSD17B10MAPTGLO1
Alcohol SCHEMBL3398638 0.77 ALDH1A1 (0.56) ALDH1A1LMNAHSD17B10MAPTGLO1
Alcohol SCHEMBL7251358 0.76 GAA (0.67) ALDH1A1LMNAHSD17B10MAPTGAA
SCHEMBL1680531 0.76 GAA (0.67) ALDH1A1LMNAHSD17B10MAPTGLO1
SCHEMBL6129631 0.76 EGLN1 (0.54) ALDH1A1LMNAHSD17B10MAPTGLO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960383-B2 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease LABORATORIOS ALMIRALL SA (ES) 2011-06-14 US disclosed
EP-1758869-B1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS ALMIRALL SA (ES) 2010-12-22 EP disclosed
US-20080280918-A1 Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors ALMIRALL PRODESFARMA, SA (ES) 2008-11-13 US disclosed
EP-1758869-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2007-03-07 EP disclosed
WO-2005123692-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS LABORATORIOS ALMIRALL, S.A. (ES) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280918-A1 Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors PDE12, PDE4A, PDE4B ALDH1A1 457/4885LMNA 4296/4885HSD17B10 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.